Fig. 1.

Cumulative incidence of discontinuation of RA treatment over 6 months in cohort A (baricitinib) and cohort B (ts/bDMARDs). Cumulative incidence developed with reverse Kaplan–Meier estimate. Patients with sustained clinical response were excluded from the primary outcome analysis. Patients who were lost to follow-up for any reason, including death, were censored at the last observation available. bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, RA rheumatoid arthritis, tsDMARD targeted synthetic disease-modifying antirheumatic drug